[1]
|
C. Camma, M. Giunta, F. Fiorica, L. Pagliaro, A. Craxi and M. Cottone, “Preoperative Radiotherapy for Resectable Rectal Cancer: A Meta-Analysis,” Journal of the American Medical Association, Vol. 284, No. 8, 2000, pp. 1008-1015. doi:10.1001/jama.284.8.1008
|
[2]
|
Colorectal Cancer Collaborative Group, “Adjuvant Radiotherapy for Rectal Cancer: A Systematic Overview of 8,507 Patients from 22 Randomised Trials,” Lancet, Vol. 358, No. 9290, 2001, pp. 1291-1304.
doi:10.1016/S0140-6736(01)06409-1
|
[3]
|
J. F. Bosset, L. Collette, G. Calais, L. Mineur, P. Maingon, L. Radosevic-Jelic, A. Daban, E. Bardet, A. Beny and J. C. Ollier, EORTC Radiotherapy Group Trial 22921, “Chemotherapy with Preoperative Radiotherapy in Rectal Cancer,” The New England Journal of Medicine, Vol. 355, 2006, pp. 1114-1123. doi:10.1056/NEJMoa060829
|
[4]
|
S. Fujii, S. Kitano, K. Ikenaka and T. Shirasaka, “Effect of coadministration of Uracil Or Cytosine on the Anti-Tumor Activity of Clinical Doses of 1-(2-Tetrahy-drofuryl)-5-Fluorouraciland Level of 5-Fluorouracil in Rodents,” Japanese Journal of Cancer Research: Gann, Vol. 70, No. 2, 1979, pp. 209-214.
|
[5]
|
T. Shirasaka, Y. Shimamato, H. Ohshimo, M. Yamaguchi, T. Kato, K. Yonekura and M. Fukushima, “Development of A Novel Form of an Oral 5-Fluorouracil Derivative (S-1) Directed to the Potentiation of the Tumor Selective Cytotoxicity of 5-Fluorouracil by Two Biochemical Modulators,” Anti-Cancer Drugs, Vol. 7, No. 5, 1996, pp. 548-557. doi:10.1097/00001813-199607000-00010
|
[6]
|
T. Shirasaka, K. Nakano, T. Takechi, H. Satake, J. Uchida, A. Fujioka, H. Saito, H. Okabe, K. Oyama, S. Takeda, N. Unemi and M. Fukushima, “Antitumor Activity of 1 M Tegafur-0.4 M 5-Chloro-2,4-Dihydroxypyridine-1 M Potassium Oxonate (S-1) Against Human Colon Carcinoma Orthotopically Implanted into Nude Rats,” Cancer Research, Vol. 56, No. 11, 1996, pp. 2602-2606.
|
[7]
|
P. M. Hoff, N. Janjan, E. D. Saad, J. Skibber, C. Crane, Y. Lassere, K. R. Cleary, S. Benner, J. Randolph, J. L. Abbruzzese and R. Pazdur, “Phase I Study of Preoperative Oral Uracil and Tegafur plus Leucovorin and Radiation Therapy in Rectal Cancer,” Journal of Clinical Oncology, Vol. 18, No. 20, 2000, pp. 3529-3534.
|
[8]
|
J. Feliu, J. Calvilio, A. Escribano, J. de Castro, M. E. Sanchez, A. Mata, E. Espinosa, A. G. Grande, A. Mateo, M. G. Baron, “Neoadjuvant Therapy of Rectal Carcinoma with Uft-Leucovorin plus Radiotherapy,” Annals of Oncology, Vol. 13, No. 5, 2002, pp. 730-736.
doi:10.1093/annonc/mdf116
|
[9]
|
L. W. Vestermark, A. Jacobsen, C. Qvortrup, F. Hansen C. Bisgaard, G. Baatrup, P. Rasmussen and P. Pfeiffer, “Long-Term Results of a Phase II Trial of High Dose Radiotherapy (60 Gy) and UFT/l-Leucovorin in Patients with Non-Resectable Locally Advanced Rectal Cancer (LARC),” Acta Oncologica, Vol. 47, No. 3, 2008, pp. 428-433. doi:10.1080/02841860701798866
|
[10]
|
C. Fernández-Martos, J. Aparicio, C. Bosch, M. Torregrosa, J. M. Campos, S. Garcera, J. M. Vicent, I. Maestu, M. A. Climent, J. L. Mengual, A. Tormo, A. Hernandez, R. Estevan J. M. Richart, V. Viciano, N. Uribe, J. Campos, R. Puchades F. Arlandis and D. Almenar, “Preoperative Uracil, Tegafur, and Concomitant Radiotherapy in Operable Rectal Cancer: A Phase II Multicenter Study with 3 Years’ Follow-Up,” Journal of Clinical Oncology, Vol. 22, 15, 2004, pp. 3016-3022.
doi:10.1200/JCO.2004.11.124
|
[11]
|
A. de la Torre, M. I. García-Berrocal, F. Arias, I. Zapata, C. de la Fuente, E. Fernandez-Lizarbe, G. Vergara, B. Belinchon, M. Veiras, R. Moleron and I. Millan, “Preoperative Chemoradiotherapy for Rectal Cancer: Randomized Trial Comparing Oral Uracil and Tegafur and Oral Leucovorin vs. Intravenous 5-Fluorouracil and Leucovorin,” International Journal of Radiation Oncology, Biology, Physics, Vol. 70, No. 1, 2008, pp. 102-110.
doi:10.1016/j.ijrobp.2007.05.068
|
[12]
|
M. Fukushima, K. Sakamoto, M. Sakata, F. Nakagawa, H. Saito and Y. Sakata, “Gimeracil, a Component of S-1, May Enhance the Antitumor Activity of X-Ray Irradiation in Human Cancer Xenograft Models in Vivo,” Oncology Reports, Vol. 24, No. 5, 2010, pp. 1307-1313.
doi:10.3892/or_00000987
|
[13]
|
S. Morimoto, M. Shimada, N. Kurita, H. Sato, T. Iwata, M. Nishioka, K. Yoshikawa, T. Miyatani, H. Kashihara, C. Takasu and H. Ikushima, “Preoperative Radiotherapy Combined with S-1 for Advanced Lower Rectal Cancer: Phase I Trial,” Hepatogastroenterology, Vol. 59, No. 117, 2012, pp. 1428-1432. doi:10.5754/hge11699
|
[14]
|
“Response Assessment of Nonsurgical Treatment for Colorectal Carcinoma. Japanese Classification of Colorectal Carcinoma. Japanese Society for Cancer of the Colon and Rectum, “1st English Edition, Kanehara & Co. Ltd., Tokyo, 1997, pp. 77-82.
|
[15]
|
R. Glynne-Jones, J. Dunst and D. Sebag-Montefiore, “The Integration of Oral Capecitabine into Chemoradiation Regimens for Locally Advanced Rectal Cancer: How Successful Have We Been?” Annals of Oncology, Vol. 17, 3, 2006, pp. 361-371. doi:10.1093/annonc/mdj052
|
[16]
|
N. A. Janjan, J. Abbruzzese, R. Pazdur, V. S. Khoo, K. Cleary, R. Dubrow, J. Ajani, T. A. Rich, M. S. Goswitz, P. A. Evetts, P. K. Allen, P. M. Lynch and J. M. Skibber, “Prognostic Implications of Response to Preoperative Infusional Chemoradiation in Locally Advanced Rectal Cancer,” Radiotherapy & Oncology, Vol. 51, No. 2, 1999, pp. 153-160. doi:10.1016/S0167-8140(99)00054-7
|
[17]
|
J. Dunst, T. Reese, T. Sutter, H. Zu¨hlke, A. Hinke, K. Ko¨lling-Schlebusch and S. Frings, “Phase I Trial Evaluating the Concurrent Combination of Radiotherapy and Capecitabine in Rectal Cancer,” Journal of Clinical Oncology, Vol. 20, No. 19, 2002,3983-3991.
doi:10.1200/JCO.2002.02.049
|
[18]
|
J. Souglakos, N. Androulakis, D. Mavroudis, C. Kourousis, S. Kakolyris, N. Vardakis, K. Kalbakis, A. Pallis, A. Ardavanis, C. Varveris and V. Georgoulias, “Multicenter Dose-Finding Study of Concurrent Capecitabine and Radiotherapy as Adjuvant Treatment for Operable Rectal Cancer,” International Journal of Radiation Oncology, Biology, Physics, Vol. 56, No. 5, 2003, pp. 1284-1287. doi:10.1016/S0360-3016(03)00275-X
|
[19]
|
I. Craven, A. Crellin, R. Cooper, A. Melcher, P. Byrne and D. Sebag-Montefiore, “Preoperative Radiotherapy Combined with 5 Days Per Week Capecitabine Chemotherapy in Locally Advanced Rectal Cancer,” British Journal of Cancer, Vol. 97, No. 10, 2007, pp. 1333-1337.
doi:10.1038/sj.bjc.6604042
|
[20]
|
C. Aschele, C. Pinto, S. Cordio, G. Rosati, A. Tagliagambe, S. Artale, P. Rosetti, S. Lonardi, L. Boni and L. Cionini, “Preoperative Fluorouracil (FU)-Based Chemoradiation with and Without Weekly Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Response Analysis of the Studio Terapia Adiuvante Reto (STAR)-01 Randomized Phase III Trial (Abstract #4008),” Journal of Clinical Oncology, Vol. 27, 2009, p. 804s.
|
[21]
|
J. Gerard, D. Azria, S. Gourgou-Bourgade, I. Martel-Laffay, C. Hennequin, P. L. Etienne, V. Vendrely, E. Francois, G. de La Roche, O. Bouche, X. Mirabel, B. Denis, L. Mineur, J. F. Berdah, M. A. Mahe, Y. Becouarn, O. Dupuis, G. Lledo, C. Montoto-Grillot and T. Conroy, “Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2,” Journal of Clinical Oncology, Vol. 28, No. 10, 2010, pp. 1638-1644. doi:10.1200/JCO.2009.25
|
[22]
|
T. Sato, H. Ozawa, K. Hatate, W. Onosato, M. Naito, T. Nakamura, A. Ihara, W. Koizumi, K. Hayakawa, I. Okayasu, K. Yamashita and M. Watanabe, “A Phase II Trial of Neoadjuvant Preoperative Chemoradiotherapy with S-1 plus Irinotecan and Radiation in Patients with Locally Advanced Rectal Cancer: Clinical Feasibility and Response Rate,” International Journal of Radiation Oncology, Biology, Physics, Vol. 79, No. 3, 2011, pp. 677-683.
doi:10.1016/j.ijrobp.2009.11.007
|
[23]
|
B. Glimelius, U. Isacsson, B. Jung and L. Pahlman, “Radiotherapy in Addition to Radical Surgery in Rectal Cancer: Evidence for a Dose-Response Effect Favoring Preoperative Treatment,” International Journal of Radiation Oncology, Biology, Physics, Vol. 37, No. 2, 1997, pp. 281-287. doi:10.1016/S0360-3016(96)00510-X
|
[24]
|
K. L. Wiltshire, I. G. Ward, C. Swallow, C. S. Wong, R. Wong, L. L. Siu, M. Moore and J. Brierley, “Preoperative Radiation with Concurrent Chemotherapy for Resectable Rectal Cancer: Effect of Dose Escalation on Pathologic Complete Response, Local Recurrence-Free Survival, Disease-Free Survival, and Overall Survival,” International Journal of Radiation Oncology, Biology, Physics, Vol. 64, No. 3, 2006, pp. 709-716.
doi:10.1016/j.ijrobp.2005.08.012
|
[25]
|
M. Mohiuddin, W. F. Regine, W. J. John, P. F. Hagihara, P. C. McGrath, D. E. Kenady and G. Marks, “Preoperative Chemoradiation in Fixed Distal Rectal Cancer: Dose Time Factors for Pathological Complete Response,” International Journal of Radiation Oncology, Biology, Physics, Vol. 46, No. 4, 2000, pp. 883-888.
doi:10.1016/S0360-3016(99)00486-1
|